Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Bernie Williams is back in centerBengaluru ends slump with 35Jeremy Clarkson's Diddly Squat goes online! ExFlorida sues ACC seeking records in dispute with FSU over conference exit feesNew home for University of Kentucky cancer center will help accelerate research, director saysLuna County corporal is charged for his role in deadly 2023 crash while responding to a callUS to pull troops from Chad and Niger as the African nations question its counterterrorism roleGOP mulls next move after Kansas governor vetoes effort to help Texas in border security fightMLB Players Weekend returns from Aug. 16Biden celebrates computer chip factories, pitching voters on American 'comeback'
3.5251s , 6500.5234375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Glance news portal